SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-014769
Filing Date
2024-01-25
Accepted
2024-01-25 06:06:59
Documents
13
Period of Report
2024-01-25
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d115183d8k.htm   iXBRL 8-K 29197
2 EX-99.1 d115183dex991.htm EX-99.1 5109
  Complete submission text file 0001193125-24-014769.txt   163682

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA algs-20240125.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE algs-20240125_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE algs-20240125_pre.xml EX-101.PRE 11712
7 EXTRACTED XBRL INSTANCE DOCUMENT d115183d8k_htm.xml XML 3480
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Filer) CIK: 0001799448 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39617 | Film No.: 24558477
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)